BAROSTIM THERAPY™ In Heart Failure With Preserved Ejection Fraction

Summary:

The CVRx BAROSTIM THERAPY in Heart Failure with Preserved Ejection Fraction (HFpEF) Registry will be performed with subjects who have been recently implanted with the BAROSTIM NEO System in accordance with CE-Mark approved criteria for resistant hypertension and have evidence of HFpEF per the registry enrollment criteria. Subjects must be enrolled within 30 days from implant but prior to therapy activation. Up to 70 subjects will be enrolled at up to 10 sites. Data should be obtained from standard of care measurements taken prior to implant, at enrollment/baseline, and at 3 and 6 months after the device was implanted, at which time each subject will be exited from the registry.

Eligibility Criteria:

The CE-Mark approved indications and contraindications for the BAROSTIM NEO system in the treatment of resistant hypertension include:

• Indications

  • Systolic blood pressure greater than or equal to 140 mmHg, and

  • Resistance to maximally tolerated therapy with a diuretic and two other anti-hypertension medications

• Contraindications

  • Bilateral carotid bifurcations located above the level of the mandible

  • Baroreflex failure or autonomic neuropathy

  • Uncontrolled, symptomatic cardiac bradyarrhythmias

  • Carotid atherosclerosis that is determined by ultrasound or angiographic evaluation to be greater than 50%

  • Ulcerative plaques in the carotid artery as determined by ultrasound or angiographic evaluation